NCT00920426View on ClinicalTrials.gov

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 9, 2009

Primary Completion Date

August 13, 2009

Study Completion Date

August 13, 2009

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

GSK1265744 30mg

GSK1265744 30 mg

DRUG

Placebo

Placebo to match GSK1265744

DRUG

GSK1265744 5mg

GSK1265744 5mg

Trial Locations (4)

28209

GSK Investigational Site, Charlotte

32803

GSK Investigational Site, Orlando

32960

GSK Investigational Site, Vero Beach

33308

GSK Investigational Site, Fort Lauderdale

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (2)

Shionogi
GlaxoSmithKline
All Listed Sponsors
collaborator

Shionogi

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY